Ads
related to: which osteoporosis drug is safest brand of cream for women with small faceswiserlifestyles.com has been visited by 100K+ users in the past month
smartholidayshopping.com has been visited by 1M+ users in the past month
Search results
Results From The WOW.Com Content Network
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...
Bazedoxifene is used in the prevention of postmenopausal osteoporosis. [5] Osteoporosis represents a major public health concern, especially as the number of postmenopausal women continues to rise. As a result, the need for innovative treatments has become increasingly important.
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [ 4 ] Use is often recommended together with vitamin D , calcium supplementation , and lifestyle changes.
Zoledronic acid, also known as zoledronate and sold under the brand name Zometa among others, [7] by Novartis among others, is a medication used to treat a number of bone diseases. [3] These include osteoporosis , high blood calcium due to cancer , bone breakdown due to cancer, Paget's disease of bone [ 3 ] and Duchenne muscular dystrophy (DMD).
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. [6] For osteoporosis it is less preferred than bisphosphonates. [6] It is also used to reduce the risk of breast cancer in those at high risk. [6] It is taken by mouth. [6]
In May 2003, the US Food and Drug Administration (FDA) approved ibandronate as a daily treatment for post-menopausal osteoporosis. [medical citation needed] The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis.